2026 Agenda: Day 1 - Monday 12 JanuaryMonday, 12 January 2026 - PT (Pacific Time, GMT-08:00)

A candid conversation exploring the latest trends in funding, the impact of FDA and IRA policy changes, and strategies for building commercial value from the earliest stages of development. Real-world insights on securing investment, adapting to new policy frameworks, and making strategic decisions that drive growth and patient impact.

Biotech founders preparing for Series B, investors evaluating early-stage assts, or commercial leaders sharing your launch strategy, this session offers actionable perspectives on risk management, value creation, and the milestones that matter most.

Evolving regulatory and policy dynamics are reshaping the biopharma ecosystem—impacting approval timelines, funding pathways, and market strategy. This session brings together industry and policy experts to discuss what lies ahead for biotech companies and how to navigate change to drive innovation and growth.

The Syneos Health Dealmakers’ Intentions Study is a forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries. Now in its 17th year, this survey provides a unique perspective on these trends by surveying business development professionals from pharmaceutical and biotechnology companies of all sizes to create forward-looking insights based on dealmakers' general expectations for activity in the coming year. This session will discuss the results of this year’s Dealmakers’ Intentions Study, providing a prospective view of the partnering and licensing landscape for the year ahead.

Join our panel of experts as they explore the latest strategies for forging successful partnerships, structuring high-impact deals, and driving collaborative innovation in the competitive landscape.